Texas Permanent School Fund Corp Has $956,000 Holdings in The Cooper Companies, Inc. $COO

Texas Permanent School Fund Corp trimmed its position in shares of The Cooper Companies, Inc. (NASDAQ:COO) by 36.4% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 13,432 shares of the medical device company’s stock after selling 7,681 shares during the quarter. Texas Permanent School Fund Corp’s holdings in Cooper Companies were worth $956,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also recently added to or reduced their stakes in COO. Caldwell Trust Co acquired a new stake in Cooper Companies in the second quarter valued at approximately $274,000. Orion Porfolio Solutions LLC raised its holdings in shares of Cooper Companies by 840.5% during the 2nd quarter. Orion Porfolio Solutions LLC now owns 96,592 shares of the medical device company’s stock valued at $6,873,000 after purchasing an additional 86,322 shares in the last quarter. Squarepoint Ops LLC lifted its stake in shares of Cooper Companies by 116.5% in the 2nd quarter. Squarepoint Ops LLC now owns 42,134 shares of the medical device company’s stock valued at $2,998,000 after purchasing an additional 22,676 shares during the last quarter. State of Wyoming acquired a new stake in shares of Cooper Companies in the 2nd quarter valued at $220,000. Finally, Westwood Holdings Group Inc. boosted its holdings in Cooper Companies by 23.4% in the second quarter. Westwood Holdings Group Inc. now owns 311,745 shares of the medical device company’s stock worth $22,184,000 after purchasing an additional 59,190 shares in the last quarter. Institutional investors and hedge funds own 24.39% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have weighed in on COO. Piper Sandler restated an “overweight” rating and set a $94.00 target price (up from $83.00) on shares of Cooper Companies in a report on Friday, December 5th. Morgan Stanley raised their price objective on Cooper Companies from $76.00 to $83.00 and gave the company an “equal weight” rating in a research note on Monday, December 8th. KeyCorp restated a “sector weight” rating on shares of Cooper Companies in a report on Friday, December 5th. Stifel Nicolaus set a $95.00 price target on Cooper Companies and gave the company a “buy” rating in a report on Friday, December 5th. Finally, The Goldman Sachs Group reissued a “sell” rating and issued a $71.00 price target (up previously from $64.00) on shares of Cooper Companies in a research report on Monday, December 8th. One analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, five have issued a Hold rating and two have given a Sell rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $90.15.

Cooper Companies Stock Performance

Shares of NASDAQ COO opened at $82.32 on Thursday. The Cooper Companies, Inc. has a 12 month low of $61.78 and a 12 month high of $100.24. The company has a market cap of $16.13 billion, a P/E ratio of 43.79, a P/E/G ratio of 2.36 and a beta of 1.05. The business’s 50 day moving average is $75.49 and its two-hundred day moving average is $72.30. The company has a quick ratio of 1.13, a current ratio of 1.89 and a debt-to-equity ratio of 0.30.

Cooper Companies (NASDAQ:COO) last posted its quarterly earnings data on Thursday, December 4th. The medical device company reported $1.15 earnings per share for the quarter, beating the consensus estimate of $1.11 by $0.04. Cooper Companies had a return on equity of 10.02% and a net margin of 9.16%.The company had revenue of $1.07 billion during the quarter, compared to analysts’ expectations of $1.06 billion. During the same period in the prior year, the business earned $1.04 earnings per share. Cooper Companies’s revenue for the quarter was up 4.6% compared to the same quarter last year. Cooper Companies has set its FY 2026 guidance at 4.450-4.600 EPS and its Q1 2026 guidance at 1.020-1.040 EPS. On average, equities analysts expect that The Cooper Companies, Inc. will post 3.98 EPS for the current year.

Cooper Companies announced that its board has authorized a share buyback program on Wednesday, September 17th that allows the company to buyback $2.00 billion in outstanding shares. This buyback authorization allows the medical device company to reacquire up to 15.4% of its stock through open market purchases. Stock buyback programs are usually a sign that the company’s board of directors believes its shares are undervalued.

Cooper Companies News Summary

Here are the key news stories impacting Cooper Companies this week:

• Positive Sentiment: Experienced board addition — CooperCompanies appointed Walter M. Rosebrough Jr., former STERIS CEO, as an independent director effective Jan. 3, 2026. His track record in medical devices and the Board’s pledge to consider him for Chair by end‑2026 are being viewed as a credibility and governance upgrade that could support strategic execution. CooperCompanies Appoints Walter M Rosebrough, Jr to its Board of Directors
• Positive Sentiment: Insider buying — Director Cynthia L. Lucchese bought 1,784 shares at ~$84.06 on Dec. 22, increasing her stake ~23%. Recent insider purchases are often read as confidence signals and can support sentiment while the market evaluates governance changes. SEC Filing — Insider Purchase
• Neutral Sentiment: Cooperation agreement and filings — The Company entered a cooperation agreement with Browning West, which includes standstill/voting commitments and an 8‑K disclosure. These formalize the arrangement but don’t immediately change fundamentals; investors should read the filed agreement for specifics on governance and timing. Press Release / 8‑K Disclosure
• Neutral Sentiment: Short‑interest data appears unreliable — a December entry shows “0 shares” and NaN changes; treat that as a data anomaly rather than a market signal until exchanges/feeds correct the figure.
• Negative Sentiment: Activist/uncertainty risk — Browning West’s involvement signals prior shareholder dissatisfaction. While cooperative now, the process of board refresh, potential shifts in capital allocation or strategic priorities, and transition risk can create short‑term volatility until execution clarity arrives. Quiver Quant — Cooperation Agreement Summary

Insider Activity at Cooper Companies

In other news, insider Holly R. Sheffield purchased 1,230 shares of the stock in a transaction that occurred on Tuesday, December 16th. The shares were purchased at an average cost of $80.75 per share, for a total transaction of $99,322.50. Following the completion of the purchase, the insider directly owned 39,052 shares of the company’s stock, valued at approximately $3,153,449. The trade was a 3.25% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Cynthia L. Lucchese acquired 1,784 shares of Cooper Companies stock in a transaction on Monday, December 22nd. The stock was purchased at an average price of $84.06 per share, with a total value of $149,963.04. Following the transaction, the director directly owned 9,445 shares in the company, valued at approximately $793,946.70. This trade represents a 23.29% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. In the last 90 days, insiders have purchased 18,014 shares of company stock worth $1,441,196. Insiders own 1.98% of the company’s stock.

Cooper Companies Profile

Cooper Companies, Inc (NASDAQ: COO) is a global medical device company headquartered in San Ramon, California. Founded in 1958, the company has grown through strategic acquisitions and organic development to become a major provider of vision care and women’s health products. Cooper Companies operates through two primary business segments—CooperVision and CooperSurgical—each serving specialized markets within the healthcare industry.

The CooperVision segment develops, manufactures and markets a broad range of soft contact lenses, as well as related accessories.